A 72-year-old man from Mumbai is found to have PSA 8.2 ng/mL on routine screening. DRE is unremarkable (smooth, mobile prostate). Transrectal ultrasound-guided biopsy shows adenocarcinoma in 2 of 12 cores, Gleason score 6 (3+3), involving <50% of one core. Staging MRI shows no extraprostatic extension (cT1c). Bone scan is negative. The patient is fit with no comorbidities and life expectancy >15 years. After counseling on all options, what is the most appropriate management?

Explanation

## Risk Stratification This patient has **low-risk prostate cancer** by D'Amico criteria: - **Gleason 6 (3+3)** — lowest grade - **PSA 8.2** — intermediate, but with favorable biopsy features - **cT1c** — clinically localized, impalpable - **Minimal tumor burden** (2/12 cores, <50% involvement) **Key Point:** Low-risk prostate cancer in a fit, long-life-expectancy patient is best managed by **active surveillance (AS)**, not immediate curative therapy. [cite:Harrison 21e Ch 97] ### Why Active Surveillance Is Correct 1. **Evidence-based:** Multiple RCTs (PIVOT, ProtecT) show that **immediate surgery/RT does not improve overall survival** compared to AS in low-risk disease. 2. **Avoids overtreatment:** Gleason 6 tumors have **very low metastatic potential**; many are indolent and never progress clinically. 3. **Preserves quality of life:** Radical surgery and RT carry significant morbidity (erectile dysfunction, incontinence, bowel toxicity) that is unjustified in low-risk disease. 4. **Structured protocol:** AS includes: - PSA every 6–12 months - DRE annually - Repeat biopsy if PSA velocity >0.75 ng/mL/year or PSA doubling time <3 years - Transition to curative therapy only if progression detected **High-Yield:** **Gleason ≤6 + PSA <10 + cT1c = Active Surveillance** is the standard of care in fit patients with >15-year life expectancy. [cite:NCCN Prostate Cancer Guidelines 2023] ### Why Other Options Are Inappropriate | Option | Rationale for Rejection | |--------|-------------------------| | **Radical prostatectomy** | Curative intent surgery is overtreatment for low-risk disease; causes unnecessary morbidity (incontinence, ED) without OS benefit. | | **EBRT + ADT** | Multimodal therapy is reserved for intermediate/high-risk disease. Gleason 6 does not warrant RT ± ADT. | | **Brachytherapy alone** | Monotherapy is suboptimal for PSA 8.2; reserved for selected low-risk cases but AS is preferred first-line. | **Clinical Pearl:** The **Gleason 6 paradox**: Gleason 6 on biopsy is often **not truly Gleason 6 on radical prostatectomy specimen** (upgrading occurs in ~25–30%), but this does not change the AS recommendation — the biopsy result is what we act on, and AS allows safe monitoring for grade migration. **Mnemonic:** **LRPC** (Low-Risk Prostate Cancer) → **AS First** (Active Surveillance is first-line, not surgery/RT).